A Phase Ib/III Study to Evaluate the Efficacy and Safety of Afuresertib Plus Fulvestrant in Patients with Locally Advanced or Metastatic HR+ /HER2- Breast Cancer Who Failed Standard of Care Therapies
| Title | A Phase Ib/III Study to Evaluate the Efficacy and Safety of Afuresertib Plus Fulvestrant in Patients with Locally Advanced or Metastatic HR+ /HER2- Breast Cancer Who Failed Standard of Care Therapies |
|---|---|
| Description | It is a Phase Ib/III study to evaluate the efficacy and safety of the combination therapy with afuresertib plus fulvestrant (afuresertib/placebo plus fulvestrant in Phase III) in patients with HR+/HER2- breast cancer who have failed 1 to 2 prior lines of endocrine therapy with/without a CDK4/6 inhibitor (up to 1 therapy), and/or chemotherapy (up to 1 chemotherapy) as described in the inclusion criteria. |
| Organism | Homo sapiens |
| Data Type | Metabolome Data by Mass Spectrometry (MS) |
| Data Accessibility | Controlled-access |
| BioProject | PRJCA012446 |
| Release Date | 2022-11-04 |
| Submitter | Binghe Xu (xubinghe@csco.org.cn) |
| Organization | Cancer Hospital, Chinese Academy of Medical Sciences |
| Submission Date | 2022-10-12 |
HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client).
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download Times | Download |
|---|---|---|---|---|---|---|---|
| OMIX002041-01 | LAE205INT3101_PK_2022-OCT-17 | 1 | Metabolome Data by Mass Spectrometry (MS) | 13.6 KB | csv | 0 | Controlled |